AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T20:22:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Q1 Research Tools & Consumables Earnings: Danaher (NYSE:DHR) Impresses
Thu 15 May 25, 03:35 AMBruker and 10x Genomics settle patent dispute
Wed 14 May 25, 05:32 PMInvestors Can Find Comfort In Bruker's (NASDAQ:BRKR) Earnings Quality
Wed 14 May 25, 12:20 PMBruker Corporation (BRKR) Declined Amid NIH Funding and Tariff Uncertainty
Tue 13 May 25, 03:48 PMInternational Markets and Bruker (BRKR): A Deep Dive for Investors
Tue 13 May 25, 01:16 PMRepligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
Mon 12 May 25, 06:06 PMBruker Corporation (BRKR): Among Michael Burry Stocks with Huge Upside Potential
Sun 11 May 25, 09:12 PM3 Growth Companies Insiders Own With Earnings Growth Up To 78%
Fri 09 May 25, 05:35 PM2 Stocks Under $50 to Target This Week and 1 to Avoid
Fri 09 May 25, 04:31 AMBruker First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Thu 08 May 25, 12:38 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 21.00M | 205.20M | 546.20M | 413.90M | 393.60M |
| Minority interest | -0.30000M | -0.70000M | -3.10000M | -1.90000M | -3.50000M |
| Net income | -8.60000M | 113.10M | 427.20M | 296.60M | 277.10M |
| Selling general administrative | 946.50M | 893.80M | 730.00M | 610.80M | 564.50M |
| Selling and marketing expenses | - | - | 0.60M | -3.40000M | -3.30000M |
| Gross profit | 1567.50M | 1649.50M | 1513.30M | 1305.70M | 1209.60M |
| Reconciled depreciation | 220.30M | 183.80M | 102.10M | 88.00M | 89.10M |
| Ebit | 67.20M | 254.80M | 560.60M | 432.70M | 413.30M |
| Ebitda | 287.50M | 438.60M | 675.50M | 550.40M | 516.70M |
| Depreciation and amortization | 220.30M | 183.80M | 114.90M | 117.70M | 103.40M |
| Non operating income net other | - | - | - | -18.80000M | -19.70000M |
| Operating income | 216.60M | 253.10M | 436.90M | 432.70M | 413.30M |
| Other operating expenses | 3219.90M | 3113.30M | 2527.60M | 2068.30M | 1990.30M |
| Interest expense | 46.20M | 47.90M | 16.40M | 16.10M | 14.30M |
| Tax provision | 29.30M | 91.40M | 104.00M | 116.40M | 113.00M |
| Interest income | 14.80M | 9.30M | 7.70M | 4.10M | 0.90M |
| Net interest income | -46.70000M | -38.60000M | -6.40000M | -18.80000M | -19.70000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 29.30M | 91.40M | 117.70M | 116.40M | 113.00M |
| Total revenue | 3436.50M | 3366.40M | 2964.50M | 2530.70M | 2417.90M |
| Total operating expenses | 1350.90M | 1396.40M | 1076.40M | 843.30M | 782.00M |
| Cost of revenue | 1869.00M | 1716.90M | 1451.20M | 1225.00M | 1208.30M |
| Total other income expense net | -195.60000M | -47.90000M | 109.30M | -18.80000M | -19.70000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -8.30000M | 113.80M | 322.20M | 298.50M | 280.60M |
| Net income applicable to common shares | - | - | - | 296.60M | 277.10M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 6241.40M | 5806.70M | 4249.90M | 3618.50M | 3650.00M |
| Intangible assets | 899.60M | 912.50M | 330.50M | 270.90M | 211.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 83.10M | 100.80M | 85.80M | 202.60M | 176.60M |
| Total liab | 3731.10M | 3991.50M | 2836.60M | 2486.70M | 2565.20M |
| Total stockholder equity | 2456.50M | 1781.20M | 1377.20M | 1125.70M | 1084.60M |
| Deferred long term liab | - | - | - | 62.30M | 46.00M |
| Other current liab | 570.20M | 401.90M | 454.90M | 487.10M | 481.20M |
| Common stock | 1.80M | 1.80M | 1.70M | 1.70M | 1.70M |
| Capital stock | 1.80M | 1.80M | 1.70M | 1.70M | 1.70M |
| Retained earnings | 2361.80M | 2406.70M | 2323.80M | 1926.00M | 1659.50M |
| Other liab | - | - | - | 318.20M | 404.90M |
| Good will | 1547.70M | 1507.30M | 582.60M | 457.60M | 339.50M |
| Other assets | - | 0.00000M | - | 208.90M | 160.90M |
| Cash | 298.80M | 183.40M | 488.30M | 645.50M | 1068.20M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1279.20M | 1281.30M | 1202.10M | 913.80M | 938.50M |
| Current deferred revenue | 441.30M | 438.20M | 400.00M | 225.70M | 197.50M |
| Net debt | 1744.10M | 2061.90M | 891.30M | 573.70M | 266.00M |
| Short term debt | 51.80M | 64.60M | 144.50M | 18.70M | 112.40M |
| Short long term debt | 16.60M | 32.50M | 121.20M | 18.70M | 112.40M |
| Short long term debt total | 2042.90M | 2245.30M | 1379.60M | 1219.20M | 1334.20M |
| Other stockholder equity | 172.40M | -523.80000M | -954.30000M | -816.80000M | -568.40000M |
| Property plant equipment | - | - | - | 487.00M | 406.10M |
| Total current assets | 2212.50M | 2053.20M | 2164.20M | 2124.50M | 2471.80M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 1210.90M | 312.50M |
| Short term investments | - | - | 12.00M | 100.00M | 100.00M |
| Net receivables | 736.00M | 701.20M | 621.80M | 472.70M | 416.90M |
| Long term debt | 1852.50M | 2061.80M | 1160.30M | 1200.50M | 1221.80M |
| Inventory | 1094.60M | 1067.80M | 968.30M | 803.70M | 710.10M |
| Accounts payable | 215.90M | 234.10M | 202.70M | 182.30M | 147.40M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 11.90M | 14.10M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -79.50000M | -103.50000M | 6.00M | 14.80M | -8.20000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 1.70M | 1.70M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 1926.00M | 1659.50M |
| Treasury stock | - | - | - | -1085.00000M | -820.30000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 241.10M | 232.70M | 175.70M | -76.80000M | 70.80M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4028.90M | 3753.50M | 2085.70M | 1494.00M | 1178.20M |
| Capital lease obligations | 173.80M | 151.00M | 98.10M | 51.20M | 59.70M |
| Long term debt total | - | - | - | 1200.50M | 1221.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -7.20000M | -1757.30000M | -438.50000M | -239.30000M | -50.30000M |
| Change to liabilities | - | - | - | 30.80M | 100.60M |
| Total cashflows from investing activities | -196.50000M | -1757.30000M | - | -251.60000M | -192.40000M |
| Net borrowings | -491.30000M | 875.90M | - | 0.30M | 489.60M |
| Total cash from financing activities | 135.10M | 1229.80M | -193.40000M | -415.20000M | 318.70M |
| Change to operating activities | - | - | - | 2.60M | -19.20000M |
| Net income | 29.20M | 113.80M | 427.20M | 298.50M | 280.60M |
| Change in cash | 116.40M | -304.90000M | -157.20000M | -423.00000M | 386.20M |
| Begin period cash flow | 186.70M | 491.60M | 645.50M | 1071.70M | 685.50M |
| End period cash flow | 303.10M | 186.70M | 488.30M | 648.70M | 1071.70M |
| Total cash from operating activities | 134.10M | 251.30M | 350.10M | 262.00M | 282.40M |
| Issuance of capital stock | 677.60M | 403.00M | 6.80M | 2.80M | 7.00M |
| Depreciation | 220.30M | 183.80M | 114.90M | 88.00M | 89.10M |
| Other cashflows from investing activities | -31.80000M | 1.10M | - | -168.40000M | 10.00M |
| Dividends paid | 22.80M | 30.20M | 29.40M | 29.80M | 24.20M |
| Change to inventory | 12.10M | -69.80000M | -125.00000M | -140.10000M | -67.00000M |
| Change to account receivables | 54.20M | -40.60000M | -0.90000M | -67.90000M | -95.30000M |
| Sale purchase of stock | -10.00000M | 0.00000M | -152.30000M | -263.10000M | -153.30000M |
| Other cashflows from financing activities | -10.50000M | -18.90000M | 0.30M | -14.10000M | 492.40M |
| Change to netincome | - | - | - | 12.90M | 41.40M |
| Capital expenditures | 90.80M | 115.30M | 106.90M | 119.00M | 92.00M |
| Change receivables | - | - | - | -67.90000M | -95.30000M |
| Cash flows other operating | - | - | - | 49.20M | 26.20M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -392.50000M | 408.70M |
| Change in working capital | -144.60000M | -78.20000M | -87.80000M | -143.50000M | -125.20000M |
| Stock based compensation | 20.20M | 25.30M | 24.00M | 27.70M | 17.20M |
| Other non cash items | 133.70M | 70.40M | -103.80000M | 8.10M | 26.50M |
| Free cash flow | 43.30M | 136.00M | 243.20M | 143.00M | 190.40M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BRKR Bruker Corporation |
5.39 9.40% | 62.70 | - | 15.22 | 1.78 | 2.48 | 2.28 | 25.93 |
| ABT Abbott Laboratories |
0.02 0.02% | 86.99 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
1.70 0.58% | 295.00 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
4.20 5.69% | 77.95 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.01 0.02% | 47.69 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
40 Manning Road, Billerica, MA, United States, 01821
| Name | Title | Year Born |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & Pres | 1960 |
| Mr. Gerald N. Herman | Exec. VP & CFO | 1958 |
| Dr. Mark R. Munch Ph.D. | Corp. Exec. VP and Pres of Bruker Nano Group & Corp. | 1962 |
| Mr. Juergen Srega | Pres of Bruker CALID Group & Bruker Daltonics Division | 1955 |
| Dr. Falko Busse Ph.D. | Pres of Bruker BioSpin Group | 1967 |
| Mr. Justin Joseph Ward | Sr. Director of Investor Relations & Corp. Devel. | NA |
| Mr. J. Brent Alldredge J.D. | Gen. Counsel | 1975 |
| Mr. Collin J. D'Silva | Pres of Chemical Analysis Division | 1957 |
| Stacey Desrochers | Treasurer & Director of Investor Relations | NA |
| Mr. Urban Faeh | Pres of Bruker Optics Division & Managing Director of Bruker Optik GmbH | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...